Locus Pharmaceuticals, Inc. Initiates Strategic Inflammatory Cancer Research Collaborations

BLUE BELL, Pa.--(BUSINESS WIRE)--Locus Pharmaceuticals announced today that it has entered into significant research collaborations with The Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center, San Antonio and with the University of Texas M.D. Anderson Cancer Center (MDACC). These new collaborations center on the Locus p38 inhibitor portfolio of drug development candidates, and will build upon an existing research relationship with CTRC which focuses on LP-261, Locus’ lead clinical candidate in Phase 1. The p38 portfolio is comprised of highly selective allosteric inhibitors of p38 alpha and beta isozymes and LP-590, a multikinase inhibitor of p38, Tie-2, and Ret kinases. Both programs are in late preclinical development for the treatment of cancers characterized by angiogenesis and inflammation.

Back to news